Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug nivolumab tested in rare blood cancer

NCT ID NCT06936943

Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug nivolumab (Opdivo) in 14 people with Richter's transformation, a rare and aggressive blood cancer that arises from chronic lymphocytic leukemia. The study measures how many patients respond to treatment, how long they live, and safety. All participants receive nivolumab every 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nivolumab (Opdivo)
What this could lead to
If it works, this could offer a new treatment option for Richter's transformation, a rare and aggressive blood cancer.
What could go wrong
This is a small, early-phase study with only 14 participants, so results may not apply broadly. Nivolumab can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 14 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histological diagnosis of diffuse large B-cell lymphoma (DLBCL)-type or Hodgkin lymphoma(HL)-type Richter's transformation with a history of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) * In the case of DLBCL-type Richter's transformation, refractory, intolerant or ineligible for treatment of DLBCL * Patients with measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Expected to survive for 90 days or more Exclusion Criteria: * Serious complications * Active multiple cancers * Active central nervous system (CNS) disease * History of allogeneic hematopoietic stem cell transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Richter's transformation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Richter's transformation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aichi Cancer Center

    RECRUITING

    Nagoya, Aichi-ken, Japan

  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

    RECRUITING

    Hiroshima, Hiroshima, Japan

  • Hokkaido University Hospital

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • Kindai University Hospital

    RECRUITING

    Ōsaka-sayama, Osaka, Japan

  • Kyoto University Hospital

    RECRUITING

    Kyoto, Kyoto, Japan

  • Kyusyu University Hospital

    RECRUITING

    Fukuoka, Fukuoka, 812-8582, Japan

  • National Cancer Center Hospital

    RECRUITING

    Chuo Ku, Tokyo, Japan

  • Niigata University Medical & Dental Hospital

    RECRUITING

    Niigata, Niigata, Japan

  • Tohoku University Hospital

    RECRUITING

    Sendai, Miyagi, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

    RECRUITING

    Bunkyō-Ku, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.